Shukra Pharmaceuticals Authorized as Distributor by Integra Medical
Filing Summary
Shukra Pharmaceuticals Ltd has received an authorization letter from Integra Medical Devices India Pvt Ltd, effective December 3, 2025. This authorization designates Shukra Pharmaceuticals as the authorized distributor for all Directorate General Armed Forces Medical Services (DGAFMS) purchases across India. The agreement allows Shukra to promote, market, and supply Integra’s medical equipment to DGAFMS-affiliated projects. The authorization is valid until December 31, 2026. This development aligns with Shukra’s strategic focus on expanding its presence in the defense healthcare sector.
On December 3, 2025, Shukra Pharmaceuticals Ltd received an authorization letter from Integra Medical Devices India Pvt Ltd. This letter authorizes Shukra Pharmaceuticals to act as the authorized distributor for all purchases by the Directorate General Armed Forces Medical Services (DGAFMS) across India.
The authorization empowers Shukra Pharmaceuticals to promote, market, and supply medical equipment and devices from Integra Medical Devices for all DGAFMS-affiliated projects. These projects include defense hospitals, commands, and related defense organizations across India. Shukra will operate as the official distributor for all DGAFMS-related procurement activities from the date of the authorization letter’s issuance.
The authorization is valid until December 31, 2026, unless terminated earlier according to the terms outlined in the letter. Shukra Pharmaceuticals is required to collaborate closely with Integra Lifesciences on all projects, ensuring adherence to mutually agreed commercial terms, compliance norms, and ethical business standards.
Integra Medical Devices India Pvt Ltd focuses on providing advanced medical devices and equipment. The company prioritizes strategic partnerships to enhance its distribution network and expand its market reach in the healthcare sector.
Shukra Pharmaceuticals Ltd is engaged in the pharmaceutical sector, focusing on expanding its presence in the defense healthcare segment. The company aims to enhance its product portfolio and establish itself as a credible partner for government and defense-sector collaborations.